会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Tilt steering mechanism
    • 倾斜转向机构
    • US5836211A
    • 1998-11-17
    • US798832
    • 1997-02-12
    • William J. RossAndrew K. StitelerJerald G. Wagner
    • William J. RossAndrew K. StitelerJerald G. Wagner
    • B62D1/183B63H25/12B62D1/18
    • B63H25/12B62D1/183
    • The new tilt steering mechanism includes a housing having a tower and a pair of C-shaped clamps comprising a locking apparatus fixed with respect to the tower. Each clamp has a locking quadrant formed by alternating ridges and grooves. A swivel bar extends along a swivel axis and is trunnion-mounted for pivoting movement with respect to the tower and the clamps. An annular, ring-like locking device is mounted on the swivel bar for movement therealong and is spring biased toward the clamps. Such locking device includes a pair of wedge-shaped locking members for selectively engaging grooves in respective quadrants on the clamps. Other features for excluding dirt from the mechanism and, in the case of a mechanism used to drive a pump and steer a boat, for driving the pump and checking oil level are also disclosed.
    • 新的倾斜转向机构包括具有塔架的壳体和包括相对于塔架固定的锁定装置的一对C形夹具。 每个夹具具有通过交替的脊和凹槽形成的锁定象限。 旋转杆沿着旋转轴线延伸并且被耳轴安装以相对于塔架和夹具枢转运动。 环形的环形锁定装置安装在旋转杆上,用于在其上移动,并且朝向夹具弹簧偏置。 这种锁定装置包括一对楔形锁定构件,用于选择性地接合夹具上相应象限中的凹槽。 还公开了用于排除机构中的污垢以及在用于驱动泵并引导船的机构的情况下用于驱动泵并检查油位的其它特征。
    • 10. 发明授权
    • SRS-A antagonists
    • SRS-A拮抗剂
    • US4513005A
    • 1985-04-23
    • US386570
    • 1982-06-09
    • Stephen R. BakerWilliam B. JamiesonWilliam J. RossAlec Todd
    • Stephen R. BakerWilliam B. JamiesonWilliam J. RossAlec Todd
    • C07B45/04C07C317/46C07C323/22C07C323/56C07C323/58C07D303/40C07D303/42C07D307/38C07D309/12C07D309/30C07D313/04C07F9/53C07K5/06C07C149/20A61K31/23A61K31/335
    • C07D307/38C07B45/04C07C317/46C07C323/22C07C323/56C07C323/58C07D303/40C07D303/42C07D309/12C07D309/30C07D313/04C07F9/5304C07F9/5325C07K5/06034
    • There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, ##STR1## in which R.sub.1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C.sub.3-6 alkoxy, C.sub.3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms,(ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or(iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C.sub.1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R.sub.2 is(i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR.sub.3 and COX, where R.sub.3 is H, C.sub.1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C.sub.1-4 alkyl, NH.sub.2 or an amino acid residue, or(ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C.sub.1-4 acylamino and NHR.sub.4, where R.sub.4 is hydrogen or C.sub.1-4 alkyl; and Y is --S--, --SO-- or --SO.sub.2 --,with the proviso that when --YR.sub.2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R.sub.1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.
    • 描述了用于治疗涉及SRS-A作为因果介质的过敏性/炎症性疾病,其游离酸形式为式I的化学活性化合物,其中R 1是(i)脂族, 至少20个碳原子的饱和或不饱和烃基,未被取代或被至少一个选自卤素,羟基,C 3-6烷氧基,C 3-6环烷基,芳基或杂芳基的取代基取代,环烷基,芳基或杂芳基是未取代或取代的 至少一个选自羟基,卤素和至多10个碳原子的烷基,烯基或炔基的取代基,(ii)未被取代或被至多16个碳原子的烷基,烯基或炔基取代的3至8个碳原子的环烷基,或 (iii)未被取代或被羟基,C 1-4烷氧基,卤素或至多16个碳原子的烷基,链烯基或炔基取代的芳基或杂芳基; 并且R 2是(i)至少10个碳原子的烷基,环烷基或链烯基,未被取代或被一个或多个选自芳基,环烷基,卤素,羟基,NHR 3和COX的取代基取代,其中R 3是H,C 1-4烷基, 芳基或氨基酸残基或COX,X为OH,C 1-4烷基,NH 2或氨基酸残基,或(ii)未被取代或被一个或多个选自C 1-4烷基,C 1 -4-烷氧基,C 2-5酰基,卤素,羟基,羧基,硝基,三卤甲基,苯基,C 1-4酰基氨基和NHR 4,其中R 4是氢或C 1-4烷基; 并且Y是-S-,-SO-或-SO 2 - ,条件是当-YR 2是谷胱甘肽基,半胱氨酰基或半胱氨酰甘氨酰基时,则R 1不同于未被取代的具有12至16个碳原子的烷基四烯基或烷基五烯基。